Study Evaluating Magrolimab in Patients With TP53-Mutant AML Discontinued
Gilead has discontinued the ENHANCE-2 study, which was designed to evaluate magrolimab in AML patients with TP53 mutations.
Diagnosis & Disease Information
Vitamin C, D Supplementation During Chemo May Reduce Complications in AML
Taking vitamin C and D during chemotherapy may improve some outcomes for patients with AML, a new study suggests.
Bexmarilimab Gets Orphan Drug Status for AML
Bexmarilimab is a first-in-class, humanized monoclonal antibody designed to target Clever-1, a receptor on macrophages that leads to tumor growth and metastasis.
Risk of tMDS/AML After Common Lymphoid Neoplasms
Survivors of common lymphoid neoplasms have an increased risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia, data suggest.
Vanflyta Now Available for FLT3-ITD Positive Acute Myeloid Leukemia
Vanflyta is available only through a risk evaluation and mitigation strategy program.
Vanflyta Approved for Newly Diagnosed FLT3-ITD AML
Vanflyta is expected to be available in the coming weeks.
Spleen Volume Linked to HSCT Outcomes in AML Patients
Higher spleen volume was tied to inferior outcomes for patients with AML undergoing hematopoietic stem cell transplant.
Outcomes of Unrelated, Haplo Transplant in AML Have Improved Over Time
In recent years, outcomes have improved for AML patients undergoing unrelated or haploidentical transplant in second complete remission.
All-Oral Triplet Regimen Demonstrates Activity in Acute Promyelocytic Leukemia
An all-oral triplet regimen is safe and effective in patients with newly diagnosed acute promyelocytic leukemia, a phase 2 trial suggests.
Processed Red Meat Intake Linked to Increased Incidence of AML/MDS
Processed red meat intake is associated with an increased incidence of AML and MDS in a Japanese population, a study suggests.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...